




Barinthus Biotherapeutics plc Rank 87 of 471

The relative strengths and weaknesses of Barinthus Biotherapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Barinthus Biotherapeutics plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 122% points. The greatest weakness of Barinthus Biotherapeutics plc is the variable Other Revenues, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 383%, being 108% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	226,765
Cost of Goods Sold	0
Intangible Assets	44,060
Liabilities, Current	11,158
Liabilities, Non-Current	6,540
Other Assets	8,061
Other Compr. Net Income	-6,998
Other Expenses	-28
Other Liabilities	10,455
Other Net Income	-5,919
Other Revenues	268
Property and Equipment	1,829
Research and Development	20,371
Selling, General and Administrative Expense	25,118

Output Variable	Value in 1000 USD
Assets	280,715
Liabilities	28,153
Expenses	45,461
Revenues	268
Stockholders Equity	252,562
Net Income	-51,112
Comprehensive Net Income	-54,611
BaseVar	183,757
ECR before LimitedLiability	321%
Economic Capital Ratio	383%